Starling Oncology
STLN
45 hedge funds and large institutions have $38.2M invested in Starling Oncology in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 3 closing their positions.
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
81% more capital invested
Capital invested by funds: $21.2M → $38.2M (+$17.1M)
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
25% more funds holding
Funds holding: 36 → 45 (+9)
4.3% more ownership
Funds ownership: 20.71% → 25.01% (+4.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$1.56M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.41M |
| 3 |
CI
Cincinnati Insurance
Fairfield,
Ohio
|
+$1.21M |
| 4 |
EPA
Element Pointe Advisors
Miami,
Florida
|
+$690K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$175K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$169K |
| 2 |
PCM
Prelude Capital Management
New York
|
-$52.4K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$48.7K |
| 4 |
PI
PineBridge Investments
New York
|
-$41.7K |
| 5 |
JAIC
Josh Arnold Investment Consultant
Edina,
Minnesota
|
-$36.7K |
STLN Hedge Fund Activity: Q4 2023 in Review
45 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q4 2023, worth a combined $38.2M — up 81% from $21.2M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new STLN positions and 3 closed out — a net gain of 10 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was Kent Lake Capital, adding an estimated $1.56M. The largest seller was Diametric Capital, cutting an estimated $169K.
- 45 institutional investors held Starling Oncology (STLN) as of Q4 2023, up from 36 in Q3 2023.
- Funds reported $38.2M of Starling Oncology stock for Q4 2023, up 81% quarter-over-quarter.
- 13 funds opened new Starling Oncology positions in Q4 2023 and 3 closed out, a net change of +10 holders.
- The largest Starling Oncology buyer in Q4 2023 was Kent Lake Capital, an estimated $1.56M added.
- The largest Starling Oncology seller in Q4 2023 was Diametric Capital, an estimated $169K sold.
Based on aggregated 13F filings for Q4 2023.